- A CONJUGATE OF A CYTOTOXIC AGENT TO A CELL BINDING MOLECULE WITH BRANCHED LINKERS
-
Provided is a conjugation of cytotoxic drug to a cell-binding molecule with a side-chain linker. It provides side-chain linkage methods of making a conjugate of a cytotoxic molecule to a cell-binding ligand, as well as methods of using the conjugate in targeted treatment of cancer, infection and immunological disorders.
- -
-
Page/Page column 249
(2021/01/23)
-
- Curcumin derivative and uses thereof
-
The present invention relates to a curcumin derivative represented by a general formula (I) or a pharmaceutically acceptable salt thereof, and a preparation method thereof, a composition containing aneffective amount of the compound represented by the general formula (I) or the pharmaceutically acceptable salt thereof, and applications of the compound represented by the general formula (I) or thepharmaceutically acceptable salt thereof in preparation of drugs for treatment of cancers, fatty liver, inflammations and the like, wherein R and R are defined in the specification.
- -
-
-
- A nonpeptidic reverse-turn scaffold stabilized by urea-based dual intramolecular hydrogen bonding
-
A novel nonpeptidic reverse-turn scaffold containing urea fragments that are connected by a conformationally constrained d-prolyl-cis-1,2- diaminocyclohexane (d-Pro-DACH) linker is reported. The scaffold adopts a well-defined reverse-turn conformation tha
- Medda, Amiya K.,Park, Chul Min,Jeon, Aram,Kim, Hyunwoo,Sohn, Jeong-Hun,Lee, Hee-Seung
-
p. 3486 - 3489
(2011/09/12)
-
- IMIDAZOLIDINONYL AMINOPYRIMIDINE COMPOUNDS FOR THE TREATMENT OF CANCER
-
The present invention provides novel imidazolidinonyl aminopyrimidine compounds believed to have clinical use for treatment of cancer through inhibiting Plk1. Formula I wherein: R1 is aminomethyl, (C1-C3 alkyl)aminomethyl, di(C1-C2 alkyl)aminomethyl, N- ethyl-N-methyl-aminomethyl, 1-aminoethyl, 1-((C1-C2 alkyl)amino)-ethyl, 3,3,3- trifluoropropylaminomethyl, ethynyl, 2-hydroxy-ethoxy, 2-hydroxyethylaminomethyl, 2- cyanoethylaminomethyl, mopholin-4-ylmethyl, methoxymethoxymethyl, cyclopropyl, 1- azetidinylmethyl, 1-pyrrolidinylmethyl, or 1,3-dioxolan-2-yl; R2 is hydrogen or halo; R3 is hydrogen or halo; provided that at least one of R2 and R3 is hydrogen; R4 is hydrogen, methyl, or halo; and is a single bond that is either present or absent, or a pharmaceutically acceptable salt thereof.
- -
-
Page/Page column 24
(2008/12/06)
-